According to NCPA, nearly 3,500 pharmacists and over 150 pharmacy stakeholder organizations have supported a potential change in DIR fees in the Centers for Medicare and Medicaid Services’ (CMS) proposed pricing rule for 2020.

The proposed change would eliminate retroactive DIR fees and issue them at the point of sale.

This move would save patients an average of $200 on some of their out-of-pocket prescriptions and would save Part D beneficiaries billions of dollars according to NCPA.

Currus submitted its own comments in response to the proposed rule as did NCPA, the National Association of Chain Drugstores (NACDS), and the National Association of Specialty Pharmacy (NASP).

Currus applauds NCPA for their efforts and all the pharmacists who took the time to submit comments in support of this change. CMS’ final rule will be issued later this year.